Belgian biotech exit prompts calls for public path towards advanced therapies

EURACTIV - Belgium has become a focal point in Europe's biotech debate after the biotech company Galapagos halted development of its advanced cell therapy programme. The move follows similar withdrawals by Takeda and Novo Nordisk, both of which ended their cell therapy operations to refocus on core areas. Read more

[Getty Images]